Works by Lau, Peter


Results: 87
    1
    2
    3
    4
    5
    6
    7
    8
    9
    10

    15th August: Proper 15.

    Published in:
    Expository Times, 2010, v. 121, n. 10, p. 509, doi. 10.1177/00145246101210100503
    By:
    • Lau, Peter
    Publication type:
    Article
    11

    1st November: Proper 26.

    Published in:
    Expository Times, 2009, v. 121, n. 1, p. 27, doi. 10.1177/0014524609107035
    By:
    • Lau, Peter
    Publication type:
    Article
    12
    13
    14
    15
    16
    17
    18
    19

    Adaptive translational reprogramming of metabolism limits the response to targeted therapy in BRAF<sup>V600</sup> melanoma.

    Published in:
    Nature Communications, 2022, v. 13, n. 1, p. 1, doi. 10.1038/s41467-022-28705-x
    By:
    • Smith, Lorey K.;
    • Parmenter, Tiffany;
    • Kleinschmidt, Margarete;
    • Kusnadi, Eric P.;
    • Kang, Jian;
    • Martin, Claire A.;
    • Lau, Peter;
    • Patel, Riyaben;
    • Lorent, Julie;
    • Papadopoli, David;
    • Trigos, Anna;
    • Ward, Teresa;
    • Rao, Aparna D.;
    • Lelliott, Emily J.;
    • Sheppard, Karen E.;
    • Goode, David;
    • Hicks, Rodney J.;
    • Tiganis, Tony;
    • Simpson, Kaylene J.;
    • Larsson, Ola
    Publication type:
    Article
    20
    21

    Types of patients in a psychiatric intensive care unit.

    Published in:
    Australian & New Zealand Journal of Psychiatry, 2001, v. 35, n. 6, p. 841, doi. 10.1046/j.1440-1614.2001.00953.x
    By:
    • Wynaden, Dianne;
    • McGowan, Sunita;
    • Chapman, Rose;
    • Castle, David;
    • Lau, Peter;
    • Headford, Craig;
    • Finn, Michael
    Publication type:
    Article
    22
    23
    24
    25
    26
    27
    28

    Ruth.

    Published in:
    2014
    By:
    • Lau, Peter H. W.
    Publication type:
    Book Review
    29

    Ruth.

    Published in:
    2013
    By:
    • Lau, Peter H. W.
    Publication type:
    Book Review
    30
    31
    32
    33

    FDG PET/CT for tumoral and systemic immune response monitoring of advanced melanoma during first-line combination ipilimumab and nivolumab treatment.

    Published in:
    European Journal of Nuclear Medicine & Molecular Imaging, 2020, v. 47, n. 12, p. 2776, doi. 10.1007/s00259-020-04815-w
    By:
    • Iravani, Amir;
    • Osman, Medhat M.;
    • Weppler, Alison M.;
    • Wallace, Roslyn;
    • Galligan, Anna;
    • Lasocki, Arian;
    • Hunter, Morgan O.;
    • Akhurst, Tim;
    • Hofman, Michael S.;
    • Lau, Peter K. H.;
    • Kee, Damien;
    • Au-Yeung, George;
    • Sandhu, Shahneen;
    • Hicks, Rodney J.
    Publication type:
    Article
    34
    35
    36
    37
    38
    39
    40
    41
    43
    46
    47
    48
    49

    Why not antiglobulin compatibility testing?

    Published in:
    Transfusion, 1985, v. 25, n. 6, p. 589, doi. 10.1111/j.1537-2995.1985.tb01416.x
    By:
    • Sererat, Surapong;
    • Beatty, Jack;
    • Schifano, Joseph V.;
    • Lau, Peter
    Publication type:
    Article
    50